Mark Currie currently holds multiple leadership roles, including Chair of the Scientific Advisory Board at Prudentia Sciences and Scaffold Therapeutics, as well as a Venture Partner position at Iaso Ventures. Currie's extensive experience includes board membership at Antag Therapeutics and Sea Pharmaceuticals, as well as serving on the Board of Directors for Ironwood Pharmaceuticals and Science Exchange. Previously, Currie held the position of Chief Science Officer at Microbia and Vice President of Discovery at Sepracor Inc. Currie earned a PhD in Cell Biology and Anatomy from Wake Forest University School of Medicine and holds two Bachelor's degrees in Biology and Cell/Cellular Biology from the University of South Alabama.
This person is not in the org chart
This person is not in any teams
This person is not in any offices